{"disease":{"id":"urinary-tract-infections","name":"urinary tract infections"},"drugs":{"marketed":[{"drug_id":"zavicefta-ceftazidime-avibactam","indication_name":"Complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain susceptible bacteria.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zavicefta, Ceftazidime-Avibactam","generic_name":"zavicefta-ceftazidime-avibactam","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Bacterial cell wall synthesis","drug_class":"Cephalosporin antibiotic and beta-lactamase inhibitor combination","quality_score":55,"revenue":"638","mechanism":""},{"drug_id":"benzoic-acid","indication_name":"Relief of local symptoms in lower urinary tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benzeneformic Acid","generic_name":"benzoic acid","company_name":"","drug_phase":"marketed","molecular_target":"Nicotinate phosphoribosyltransferase","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"cefoxitin","indication_name":"Urinary tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mefoxin In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFOXITIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"cephalexin","indication_name":"Genitourinary tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEPHALEXIN","company_name":"","drug_phase":"marketed","molecular_target":"Penicillin-binding proteins (PBPs)","drug_class":"First-generation cephalosporin","quality_score":80,"revenue":null,"mechanism":"Cephalexin is a cephalosporin antibacterial drug."},{"drug_id":"fluconazole","indication_name":"Candida urinary tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diflucan","generic_name":"fluconazole","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase","drug_class":"Azole Antifungal [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"cefoxitin-sodium","indication_name":"Urinary tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFOXITIN SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":21,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1200962","indication_name":"Uncomplicated and Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFEPIME HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Cefepime is a cephalosporin antibacterial drug."},{"drug_id":"flucytosine","indication_name":"Cryptococcus Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ancobon","generic_name":"FLUCYTOSINE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Nucleoside Analog Antifungal [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"relebactam","indication_name":"Complicated Urinary Tract Infections (cUTI), including Pyelonephritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Recarbrio","generic_name":"RELEBACTAM","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Renal Dehydropeptidase Inhibitor [EPC]","quality_score":34,"revenue":null,"mechanism":"Recarbrio works by inhibiting the beta-lactamase enzymes produced by certain bacteria, allowing carbapenem antibiotics to effectively target and kill the bacteria."},{"drug_id":"ceftazidime","indication_name":"Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":75,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"amoxicillin-and-clavulanate","indication_name":"Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxicillin and clavulanate","company_name":"GlaxoSmithKline","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Amoxicillin and Clavulanate Potassium is an antibacterial drug."},{"drug_id":"chembl-chembl3989564","indication_name":"Complicated and Recurrent Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TOBRAMYCIN SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"cefuroxime-sodium","indication_name":"Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFUROXIME SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Cefuroxime inhibits bacterial cell wall synthesis, acting as a bactericidal agent."},{"drug_id":"doxycycline","indication_name":"Respiratory tract and urinary tract infections caused by Klebsiella species","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"mezlocillin","indication_name":"Genitourinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MEZLOCILLIN","company_name":"","drug_phase":"marketed","molecular_target":"Interleukin-8","drug_class":"mezlocillin","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"fusidic-acid","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"gentamicin","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Garamycin","generic_name":"GENTAMICIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 5","drug_class":"Aminoglycoside Antibacterial","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"doripenem","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doribax","generic_name":"DORIPENEM","company_name":"Shionogi","drug_phase":"marketed","molecular_target":"","drug_class":"Penem Antibacterial","quality_score":32,"revenue":null,"mechanism":""},{"drug_id":"gepotidacin","indication_name":"Uncomplicated urinary tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Blujepa","generic_name":"GEPOTIDACIN","company_name":"Glaxosmithkline","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":56,"revenue":null,"mechanism":"Blujepa works by inhibiting bacterial DNA polymerase, preventing the replication of bacterial DNA and ultimately leading to bacterial cell death."},{"drug_id":"amoxycillin","indication_name":"Genitourinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxycillin","company_name":"King George's Medical University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"cefazolin","indication_name":"Genitourinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ancef In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFAZOLIN","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"cefazolin-sodium","indication_name":"Genitourinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ancef In Sodium Chloride 0.9% In Plastic Container","generic_name":"Cefazolin Sodium","company_name":"GSK","drug_phase":"marketed","molecular_target":"Bacterial cell wall peptidoglycan","drug_class":"Cephalosporin","quality_score":60,"revenue":null,"mechanism":"Cefazolin is an antibacterial drug that inhibits bacterial cell wall synthesis."},{"drug_id":"tobramycin","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tobi","generic_name":"tobramycin","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"cefepime","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Maxipime","generic_name":"CEFEPIME","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":59,"revenue":null,"mechanism":"Cefepime is a cephalosporin antibacterial drug."},{"drug_id":"cefpodoxime","indication_name":"Uncomplicated urinary tract infections (cystitis)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefpodoxime Proxetil","generic_name":"CEFPODOXIME","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"ampicillin","indication_name":"Genitourinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"AMPICILLIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 4","drug_class":"Penicillin-class Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"cefepime-hydrochloride","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Maxipime","generic_name":"Cefepime Hydrochloride","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Bacterial cell wall peptidoglycan","drug_class":"Cephalosporin","quality_score":64,"revenue":null,"mechanism":"Cefepime is a cephalosporin antibacterial drug that inhibits bacterial cell wall synthesis."},{"drug_id":"amoxicillin","indication_name":"Genitourinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amoxil","generic_name":"amoxicillin","company_name":"Generic (originally Beecham/GSK)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"Aminopenicillin (Beta-lactam antibiotic)","quality_score":56,"revenue":null,"mechanism":"Broad-spectrum aminopenicillin that inhibits bacterial cell wall synthesis by binding penicillin-binding proteins."},{"drug_id":"cefepim","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cefepim","company_name":"University Hospital Tuebingen","drug_phase":"discontinued","molecular_target":"Bacterial penicillin-binding protein","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"tobramycin-sulfate","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantobra","generic_name":"Tobramycin Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20","drug_class":"tobramycin","quality_score":68,"revenue":null,"mechanism":""},{"drug_id":"gentamicin-sulfate","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gentamicin","generic_name":"Gentamicin Sulfate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"gentamicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Uncomplicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"nebcin","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nebcin","company_name":"University Hospital, Lille","drug_phase":"discontinued","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"atm-avi","indication_name":"Treatment of uncomplicated urinary tract infections (UTIs) caused by Escherichia coli.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of uncomplicated urinary tract infections (UTIs) caused by Klebsiella pneumoniae.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of uncomplicated urinary tract infections (UTIs) caused by Escherichia coli in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of uncomplicated urinary tract infections (UTIs) caused by Klebsiella pneumoniae in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"cephalexin","indication_name":"Genitourinary tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEPHALEXIN","company_name":"","drug_phase":"marketed","molecular_target":"Penicillin-binding proteins (PBPs)","drug_class":"First-generation cephalosporin","quality_score":80,"revenue":null,"mechanism":"Cephalexin is a cephalosporin antibacterial drug."},{"drug_id":"amikacin","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arikayce Kit","generic_name":"AMIKACIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial","quality_score":75,"revenue":null,"mechanism":"Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria."},{"drug_id":"eravacycline","indication_name":"complicated urinary tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"cefalotin","indication_name":"Genitourinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cephalotin","generic_name":"cefalotin","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 8","drug_class":"cefalotin","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TICARCILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin","indication_name":"Genitourinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TICARCILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin-disodium","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ticarcillin","generic_name":"TICARCILLIN DISODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin-disodium","indication_name":"Genitourinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ticarcillin","generic_name":"TICARCILLIN DISODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Complicated urinary tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Uncomplicated urinary tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"levofloxacin","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levaquin","generic_name":"levofloxacin","company_name":"Generic (originally Daiichi Sankyo/J&J)","drug_phase":"marketed","molecular_target":"CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2","drug_class":"Fluoroquinolone Antibacterial [EPC]","quality_score":65,"revenue":null,"mechanism":"Levofloxacin is a fluoroquinolone antibacterial agent."},{"drug_id":"cephazolin","indication_name":"Genitourinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cephazolin","company_name":"HaEmek Medical Center, Israel","drug_phase":"phase_1","molecular_target":"Bacterial penicillin-binding protein, Penicillin-binding protein 1A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cefazoline","indication_name":"Genitourinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cefazoline","company_name":"Nantes University Hospital","drug_phase":"marketed","molecular_target":"Bacterial penicillin-binding protein, Penicillin-binding protein 1A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cycloserine","indication_name":"Acute Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyclorin","generic_name":"CYCLOSERINE","company_name":"Purdue Gmp","drug_phase":"marketed","molecular_target":"Glutamate receptor ionotropic, NMDA 2A","drug_class":"cycloserine","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"amoxicilli","indication_name":"Genitourinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxicilli","company_name":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":56,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02695173","title":"Complications of UTI in Patients on Dapagliflozin","phase":"","overall_status":"COMPLETED","enrollment_count":683380,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03535558","title":"Fluoroquinolone Associated Disability","phase":"","overall_status":"COMPLETED","enrollment_count":239306,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT03612297","title":"Selective Reporting of Antibiotic Susceptibility Test Results in Urinary Tract Infections in the Outpatient Setting","phase":"","overall_status":"UNKNOWN","enrollment_count":64000,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT04239521","title":"The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata","phase":"","overall_status":"COMPLETED","enrollment_count":51955,"lead_sponsor_name":"Momentum Data","has_results":false},{"nct_id":"NCT04615065","title":"Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"University Medical Center Groningen","has_results":false},{"nct_id":"NCT05712434","title":"Chlorhexidine to Prevent Catheter-related Urinary Tract Infection","phase":"NA","overall_status":"COMPLETED","enrollment_count":30994,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT03470584","title":"Vegetarian Diet and Chronic Degenerative Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":18064,"lead_sponsor_name":"Dalin Tzu Chi General Hospital","has_results":false},{"nct_id":"NCT04408976","title":"Implementation Study With Decision Support Based on Data","phase":"","overall_status":"COMPLETED","enrollment_count":16824,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT05654909","title":"Prehospital Assessment Units - a Matched Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":10849,"lead_sponsor_name":"Prehospital Center, Region Zealand","has_results":false},{"nct_id":"NCT05385536","title":"Evaluating UTI Outcomes in at Risk Populations","phase":"","overall_status":"COMPLETED","enrollment_count":7921,"lead_sponsor_name":"Pathnostics","has_results":false},{"nct_id":"NCT06715306","title":"Intravenous Versus Oral Treatment of the Main Acute Infections","phase":"NA","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"University of Southern Denmark","has_results":false},{"nct_id":"NCT03379194","title":"Routine Antibiotic Prescription Monitoring in Primary Care Physicians: A Nationwide Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":3426,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false},{"nct_id":"NCT05091931","title":"Diagnosis, Antibiotic Prescribing Practices and Outcomes of cUTI in an Outpatient Setting","phase":"","overall_status":"COMPLETED","enrollment_count":3308,"lead_sponsor_name":"Pathnostics","has_results":false},{"nct_id":"NCT06472765","title":"Vaginal Ecosystem and Network in the United States Study","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3250,"lead_sponsor_name":"Vaginal Biome Science","has_results":false},{"nct_id":"NCT07012421","title":"Community Antibiotic Use, Susceptibility and ResisTance Among Patients With Urinary Tract Infections (CAST-UTI)","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"St George's, University of London","has_results":false},{"nct_id":"NCT06067386","title":"Selective Reporting for Antibiotic Susceptibility Testing and GPs' Prescribing of Broad-spectrum Antibiotics in Women With E. Coli UTIs","phase":"NA","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT03931538","title":"Rapid Molecular Organism Identification and Mixed Flora Antibiotic Resistance Profiling (MixAR) Prospective Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":2511,"lead_sponsor_name":"Pathnostics","has_results":false},{"nct_id":"NCT05584657","title":"Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2229,"lead_sponsor_name":"Iterum Therapeutics, International Limited","has_results":true},{"nct_id":"NCT05259683","title":"Febrile Infant Diagnostic Assessment and Outcome Study","phase":"","overall_status":"COMPLETED","enrollment_count":2076,"lead_sponsor_name":"Queen's University, Belfast","has_results":false},{"nct_id":"NCT03665467","title":"The Global Prevalence of Infections in Urology Study","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"European Association of Urology Research Foundation","has_results":false},{"nct_id":"NCT03354598","title":"Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1671,"lead_sponsor_name":"Iterum Therapeutics, International Limited","has_results":true},{"nct_id":"NCT04187144","title":"Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1606,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT04020341","title":"A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1531,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03715062","title":"Reducing Antibiotic Prescriptions for Urinary Tract Infection in Long-Term Care Facilities","phase":"NA","overall_status":"COMPLETED","enrollment_count":1491,"lead_sponsor_name":"Research Unit Of General Practice, Copenhagen","has_results":false},{"nct_id":"NCT04094818","title":"TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis","phase":"","overall_status":"COMPLETED","enrollment_count":1441,"lead_sponsor_name":"Inflammatix","has_results":false},{"nct_id":"NCT03357614","title":"Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1395,"lead_sponsor_name":"Iterum Therapeutics, International Limited","has_results":true},{"nct_id":"NCT03445312","title":"Safety and Effectiveness of a Laboratory Intervention to Effectively NOT Treat Asymptomatic Bacteriuria","phase":"","overall_status":"COMPLETED","enrollment_count":1394,"lead_sponsor_name":"Mount Sinai Hospital, Canada","has_results":false},{"nct_id":"NCT03970356","title":"Improving Antibiotic Prescribing for Urinary Tract Infections in Frail Elderly","phase":"NA","overall_status":"COMPLETED","enrollment_count":1146,"lead_sponsor_name":"Cees Hertogh","has_results":false},{"nct_id":"NCT03687255","title":"Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1043,"lead_sponsor_name":"Allecra","has_results":false},{"nct_id":"NCT03506256","title":"Noroxin Efficacy and Safety Trial","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"OBS Pakistan","has_results":false},{"nct_id":"NCT04959331","title":"Clinical Effectiveness and Bacteriological Eradication of 4 Short-course Antibiotics for Uncomplicated UTIs in Women.","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina","has_results":false},{"nct_id":"NCT05329883","title":"Multicentric Study on Infections of the Urinary Tract After Stent Removal (MINUS-trial).","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University Hospital, Ghent","has_results":false},{"nct_id":"NCT04616352","title":"Cefuroxime Resistance in Pyelonephritis","phase":"","overall_status":"COMPLETED","enrollment_count":973,"lead_sponsor_name":"Universidad Nacional de Colombia","has_results":false},{"nct_id":"NCT06091670","title":"Genital Hygiene Behaviors and Predicting Factors","phase":"","overall_status":"COMPLETED","enrollment_count":881,"lead_sponsor_name":"Istanbul University - Cerrahpasa","has_results":false},{"nct_id":"NCT03346603","title":"Prevalence of Antimicrobial-resistant Pathogens in Patients Admitted for UTIs","phase":"","overall_status":"COMPLETED","enrollment_count":801,"lead_sponsor_name":"Olive View-UCLA Education & Research Institute","has_results":false},{"nct_id":"NCT03638830","title":"Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":777,"lead_sponsor_name":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","has_results":false},{"nct_id":"NCT03184818","title":"Outcomes of Urinary Tract Infection Management by Pharmacists","phase":"","overall_status":"COMPLETED","enrollment_count":750,"lead_sponsor_name":"University of Alberta","has_results":false},{"nct_id":"NCT03045809","title":"Women's Improvement of Sexual Health (WISH) Demonstration Project","phase":"","overall_status":"COMPLETED","enrollment_count":705,"lead_sponsor_name":"Janneke van de Wijgert","has_results":true},{"nct_id":"NCT03526484","title":"The Utility of Urinalysis Prior to In-Office Procedures","phase":"NA","overall_status":"COMPLETED","enrollment_count":664,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":false},{"nct_id":"NCT03840148","title":"Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":661,"lead_sponsor_name":"Venatorx Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03744741","title":"HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections: a Multicenter Pilot Study","phase":"","overall_status":"COMPLETED","enrollment_count":585,"lead_sponsor_name":"Inflammatix","has_results":false},{"nct_id":"NCT04361864","title":"Cross-sectional Survey on Patients With Urinary Tract Infections in Puy-de-Dôme : Epidemiology of Recurrent Urinary Tract Infections and Risk Factors","phase":"","overall_status":"COMPLETED","enrollment_count":561,"lead_sponsor_name":"University Hospital, Clermont-Ferrand","has_results":false},{"nct_id":"NCT04196192","title":"Febrile Infants - Diagnostic Assessment and Outcome","phase":"","overall_status":"COMPLETED","enrollment_count":555,"lead_sponsor_name":"Belfast Health and Social Care Trust","has_results":false},{"nct_id":"NCT04608851","title":"Preventing Urinary Tract Infections With E. Coli Nissle:","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":530,"lead_sponsor_name":"University of Oulu","has_results":false},{"nct_id":"NCT05847036","title":"Profiles of Urinary Tract Infections in General Practice","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"CNGE Conseil","has_results":false},{"nct_id":"NCT04950582","title":"In Vitro Analysis of Human Urine With the CloudCath Device","phase":"","overall_status":"SUSPENDED","enrollment_count":500,"lead_sponsor_name":"CloudCath","has_results":false},{"nct_id":"NCT03790254","title":"D Mannose for Prevention and Treatment of RUTIs","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT06689280","title":"Physical Rehabilitation of Older Persons Following a Community-Acquired Infection Hospitalization - A Randomised-Controlled Trial","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":460,"lead_sponsor_name":"Nordsjaellands Hospital","has_results":false},{"nct_id":"NCT03700060","title":"Communication and Compliance for Antibiotic Prescribing by General Practice to Nursing Home Residents With Suspected UTI","phase":"","overall_status":"COMPLETED","enrollment_count":459,"lead_sponsor_name":"Research Unit Of General Practice, Copenhagen","has_results":false},{"nct_id":"NCT02321800","title":"A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":452,"lead_sponsor_name":"Shionogi","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}